简单地讲，就是许多制药行业的赢家将会失去的专利保护即将到期。
Simply put, many of the drug industry's biggest earners are about to lose their patent protections.
无品牌非专利药会使药品竞争异常激烈，以美国为例，某专利药在保护期到期后的一年内其价格降幅会超过85%。
Where competition from unbranded generics is fiercest, for instance in America, the price of a given drug falls by more than 85% within a year of patent expiry.
阿斯利康公司也寻求在巴西销售那些专利保护即将到期的产品。
AstraZeneca is seeking approval to sell cheap off-patent drugs to Brazil.
许多大型制药企业现有产品的专利保护即将到期，目前在推出新的主打药物方面有困难。
Many large pharmaceutical companies are struggling to come up with new blockbuster drugs at a time when existing products are coming off patent protection.
诺华产品序列中15%的专利保护药品，包括超级畅销的治疗心脏疾病的Diovan，在2012年都即将到期。
Patents on 15% of Novartis's portfolio of drugs, including its blockbuster heart remedy Diovan, will have expired by 2012.
诺华产品序列中15%的专利保护药品，包括超级畅销的治疗心脏疾病的Diovan，在2012年都即将到期。
Patents on 15% of Novartis's portfolio of drugs, including its blockbuster heart remedy Diovan, will have expired by 2012.
应用推荐